Vivo Capital Fund IX, L.P. 4
4 · IO Biotech, Inc. · Filed Nov 12, 2021
Insider Transaction Report
Form 4
IO Biotech, Inc.IOBT
Vivo Capital IX, LLC
10% Owner
Transactions
- Conversion
Common Stock
2021-11-09+2,365,545→ 2,365,545 total - Purchase
Common Stock
2021-11-09$14.00/sh+650,000$9,100,000→ 3,015,545 total - Conversion
Series C Preferred Stock
2021-11-09−188,168→ 0 total→ Common Stock (2,365,545 underlying)
Footnotes (2)
- [F1]Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date.
- [F2]The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Mahendra Shah, Jack Nielsen and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein